سعر ايمباكوزا 25مجم 30 قرص 2024

Empagliflozin 25 mg film-coated tablets, 30 tablets (Zeta Pharm Empacoza).

• Directory: for diabetic patients / glycemic use (brief).
• US Jardiance: reduce risk of CV death and hospitalization for HF in adults with HF; reduce risk of sustained eGFR decline/ESKD/CV death/hospitalization in adults with CKD at risk of progression; reduce risk of CV death in adults with T2DM and established CVD; improve glycemic control in adults and pediatric patients >=10 years with T2DM as adjunct to diet and exercise.Population: Adults; pediatric >=10 years for glycemic control in T2DMDailyMed (U.S. NLM)

• Most common (>=5%): urinary tract infections and female genital mycotic infections.International label, same formulation · DailyMed (U.S. NLM)

• Hypersensitivity to empagliflozin or any excipient in the product (angioedema reported).International label, same formulation · DailyMed (U.S. NLM)

• Diabetic ketoacidosis (including in T2DM); volume depletion; genitourinary infections including Fournier gangrene; hypoglycemia with insulin/secretagogues; lower limb amputation risk signal; serious hypersensitivity.International label, same formulation · DailyMed (U.S. NLM)

• Insulin or insulin secretagogues (e.g., sulfonylurea)ModerateIncreased risk of hypoglycemia; consider lower dose of insulin/secretagogue.DailyMed (U.S. NLM)

• Based on animal data showing adverse renal effects, not recommended during the second and third trimesters of pregnancy.International label, same formulation · DailyMed (U.S. NLM)
• Not recommended while breastfeeding due to potential risk to the developing kidney.International label, same formulation · DailyMed (U.S. NLM)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).